Effects of lys-arg-arg-lys-pro-gly-pro peptide, warfarin, and acetylsalicylic acid on lipid metabolism in rats with metabolic syndrome

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A comparative study of three drugs (KRRKPGP peptide, warfarin and acetylsalicylic acid) with an anticoagulant effect in the body was conducted. The drugs were administered orally in effective doses (peptide and warfarin-100 mcg/kg, acetylsalicylic acid –1 mg/kg) for 7 days to laboratory rats with metabolic syndrome induced by a high-calorie diet (HCD). After 20 hours after the last administration of the drugs, a decrease in the concentration of total cholesterol, low-density lipoprotein cholesterol, triglycerides and an increase in the concentration of high-density lipoprotein cholesterol and a slowdown in the growth of body weight in rats were detected, which persisted for 7 days after stopping their administration. The greatest hypolipidemic effect was caused by the KRRKPGP peptide.

作者简介

T. Obergan

Lomonosov Moscow State University, Faculty of Biology

Email: tobergan@mail.ru
Moscow, Russian Federation

N. Myasoedov

Institute of Molecular Genetics National Research Center “Kurchatov Institute”

Moscow, Russian Federation

T. Shubina

Lomonosov Moscow State University, Faculty of Biology

Moscow, Russian Federation

M. Grigorjeva

Lomonosov Moscow State University, Faculty of Biology

Moscow, Russian Federation

L. Lyapina

Lomonosov Moscow State University, Faculty of Biology

Moscow, Russian Federation

参考

  1. Li X., Weber N. C., Cohn D. M., et al., Hollmann M. W., DeVries J. H., Hermanides J., Preckel B. Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis // J Clin Med. 2021. V. 10. P. 2419.
  2. Bovolini A., Garcia J., Andrade M. A., Duarte J. A. Metabolic syndrome pathophysiology and predisposing factors // Int J Sports Med. 2021. V. 42. № 3. P. 199–214.
  3. Hayden M. R. Overview and new insights into the metabolic syndrome: risk factors and emerging variables in the development of type 2 diabetes and cerebrocardiovascular disease // Medicina. 2023. V. 59. № 3. P. 561.
  4. Myasoedov N. F., Lyapina L. A., Andreeva L. A., et al. The modern view on the role of glyprolines by metabolic syndrome // Med Res Rev. 2021. V. 41. № 5. P. 2823–2840.
  5. Czuprynska J., Patel J. P., Arya R. Current challenges and future prospects in oral anticoagulant therapy // Br J Haematol. 2017. V. 178. № 6. P. 838–851.
  6. Rood K.M., Patel N., DeVengencie I. M., et al. Aspirin modulates production of pro-inflammatory and pro-resolving mediators in endothelial cells // PLoS One. 2023. V. 18. 4. P. e0283163.
  7. Yamagishi S. I. Concern about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation // Cardiovasc Diabetol. 2019. V. 18. P. 12.
  8. Roy S., Bhowmik D. R., Begum R., et al. Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice // Prostaglandins and Other Lipid Mediat. 2022. V. 162. P. 106664.
  9. Angiolillo D.J., Bhatt D. L., Lanza F., et al. Pharmacokinetic/pharmacodynamics assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study // J Thromb Thrombolysis. 2019. V. 48. № 4. P. 554–562.
  10. Кытикова О.Ю., Антонюк М. В., Кантур Т. А. и др. Распространенность и биомаркеры метаболического синдрома // Ожирение и метаболизм. 2021. Т. 18. № 3. С. 302–312.
  11. Справочник Видаль. Лекарственные препараты в России. М.: Видаль Рус, 2023.
  12. Мясоедов Н. Ф., Ляпина Л. А., Оберган Т. Ю. и др. Влияние пептидов KKRRPGP (Lys-Lys-Arg-Arg-Pro-Gly-Pro) и KRRKPGP (Lys-Arg-Arg-Lys-Pro-Gly-Pro) на параметры гемостаза, липидный профиль, уровень глюкозы крови и изменение массы тела крыс на фоне метаболического синдрома и дисфункции эндотелия // Вестн. Моск. ун-та. Сер. 16. Биология. 2021. Т. 76. № 1. С. 10–17.
  13. Duparc C., Andre C., Menard J. et al. l-Lysine acts as a serotonin type 4 receptor antagonist to counteract in vitro and in vivo the stimulatory effect of serotonergic agents on aldosterone secretion in man // Horm Metab Res. 2017. № 4. P. 269–275.
  14. Shabalina A.A., Lyapina L. A., Rochev D. L., et al. In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood // Biol Bull. 2015. V. 42. № 1. P. 74–77.
  15. Григорьева М.Е., Ляпина Л. А., Шубина Т. А. и др. Защитные эффекты Pro-Gly-Pro-Arg в условиях повышенной свертываемости крови при экспериментальной гипергликемии // Тромбоз, гемостаз и реология. 2011. № 3. С. 41–46.
  16. Makki N. F. Effect of warfarin on cholesterol, LDL, HDL and TG levels in coronary artery patients with type // Biomed Pharmacother. 2016. V. 83. P. 14–21.
  17. Michlacova J., Buliková A., Zavřelová J., et al. The current role of warfarin // Vnitr Lek. 2018. V. 63. P. 957–966.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russian Academy of Sciences, 2025